Recent developments include Q1 2026 earnings disclosures, clinical trial updates showing strong progression-free survival benefits in breast cancer, and regulatory progress with FDA NDA acceptance and Priority Review designation.

• Celcuity held its Q1 2026 earnings call and released the earnings transcript on May 14, 2026, providing updates on financials and clinical progress [N1][N2].
• The company reported a wider fiscal year 2025 loss but highlighted progress toward the potential launch of gedatolisib [N3].
• VIKTORIA-1 Phase 3 trial data showed strong progression-free survival benefit in PIK3CA-mutant breast cancer patients, supporting the drug's efficacy profile [N7].
• FDA accepted Celcuity's NDA for gedatolisib with Priority Review designation, targeting a user fee goal date of July 17, 2026 [N3].
• Citizens initiated coverage of Celcuity with a market outperform recommendation in April 2026, reflecting positive market interest [N8].
• Market activity included notable option activity and stock price movements linked to clinical and regulatory news [N6].

Celcuity's lead candidate, gedatolisib, offers a novel and comprehensive approach to inhibiting the PAM pathway, potentially overcoming resistance seen with existing therapies. Positive clinical trial data, including strong progression-free survival benefits in PIK3CA-mutant breast cancer, support its therapeutic potential. FDA designations such as Fast Track and Breakthrough Therapy, along with Priority Review of the NDA, indicate regulatory recognition of its potential. The company's strong liquidity position and ongoing clinical programs in breast and prostate cancers provide a foundation for advancing toward commercialization. Successful regulatory approval and market adoption could establish gedatolisib as a differentiated treatment option in oncology.

Celcuity remains a clinical-stage company with no approved products or revenue, continuing to incur significant operating losses. The success of gedatolisib depends on positive clinical trial outcomes, regulatory approvals, and eventual market acceptance, all of which carry inherent risks. The company faces competition from larger pharmaceutical firms with greater resources. Its substantial indebtedness and reliance on external financing may constrain operational flexibility. Manufacturing and supply depend on third parties, which could pose risks. Regulatory delays or adverse trial results could materially impact the company's prospects and financial condition.

Celcuity's moat is based on its lead candidate gedatolisib's differentiated mechanism of action, which comprehensively inhibits the PAM pathway by targeting all class I PI3K isoforms and both mTOR complexes. This broad inhibition addresses adaptive resistance mechanisms that limit the efficacy of single-component inhibitors. Gedatolisib's intravenous administration and pharmacokinetic profile contribute to better patient tolerability, potentially improving treatment adherence. The company has secured FDA Fast Track and Breakthrough Therapy designations, and its extensive clinical trial program, including Phase 3 studies, supports its development progress. Exclusive licensing from Pfizer and established manufacturing partnerships further strengthen its position. However, competition from larger pharmaceutical companies and the challenges of clinical and regulatory success remain significant.

• Clinical and Regulatory Risk: Gedatolisib's approval depends on successful completion of clinical trials and regulatory review. Negative trial outcomes or regulatory delays could adversely affect the company.
• Financial Risk: Celcuity has incurred significant losses and relies on financing to fund operations. Its substantial indebtedness may limit financial flexibility and increase vulnerability to economic conditions.
• Competition Risk: The company faces competition from larger pharmaceutical and biotech companies with greater resources and established products.
• Manufacturing and Supply Risk: Dependence on third-party contract manufacturers and distributors introduces risks related to supply chain disruptions and compliance with regulatory standards.
• Market Acceptance Risk: Even if approved, gedatolisib's commercial success depends on physician adoption, reimbursement, and competitive positioning.

• Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications, primarily breast and prostate cancers [S1].
• The lead therapeutic candidate is gedatolisib, an intravenous kinase inhibitor targeting all class I PI3K isoforms and mTOR complexes (mTORC1 and mTORC2), providing comprehensive inhibition of the PI3K/AKT/mTOR (PAM) pathway [S1].
• Gedatolisib's mechanism and pharmacokinetics differentiate it from other therapies targeting PI3Kα, AKT, or mTORC1 alone or in combination [S1].
• Gedatolisib has received FDA Fast Track designation (January 2022) and Breakthrough Therapy designation (July 2022) for treatment of HR+/HER2- advanced breast cancer (ABC) after progression on CDK4/6 therapy [S1].
• The Phase 3 VIKTORIA-1 trial evaluates gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- ABC patients post-CDK4/6 inhibitor treatment; enrollment completed with 754 subjects across nearly 200 sites globally [S1].
• VIKTORIA-1 trial cohorts are stratified by PIK3CA mutation status: cohort 1 (wild-type) reported detailed results in 2025; cohort 2 (mutant) completed enrollment with topline data anticipated in Q2 2026 [S1].
• The Phase 3 VIKTORIA-2 trial is ongoing, evaluating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as first-line treatment for endocrine treatment resistant HR+/HER2- ABC; safety run-in completed Q1 2026 [S1].
• A Phase 1b/2 trial (CELC-G-201) is ongoing, testing gedatolisib with darolutamide in metastatic castration resistant prostate cancer (mCRPC); preliminary Phase 1 data reported in Q4 2025 [S1].
• Gedatolisib is administered intravenously on a four-week cycle, which is better tolerated than oral PI3K or mTOR inhibitors, with lower rates of severe hyperglycemia and treatment discontinuation [S1].
• Clinical data show gedatolisib is more potent and efficacious than single-component PAM inhibitors in breast cancer cell lines, with cytotoxic effects and comparable activity regardless of PIK3CA mutation status [S1].
• As of December 31, 2025, 1,127 patients and healthy volunteers have received gedatolisib in 12 clinical trials, including 123 patients treated with gedatolisib as a single agent [S1].
• Celcuity has a license agreement with Pfizer for gedatolisib, including milestone payments and tiered royalties on sales [S1].
• The company relies on third-party contract manufacturing organizations (CMOs) for formulation, manufacturing, and distribution of gedatolisib for clinical and potential commercial supply [S1].
• As of March 31, 2026, Celcuity had $145.2 million in cash and equivalents, $241.9 million in short-term investments, total current assets of $408.9 million, and current liabilities of $33.2 million, resulting in a current ratio of 12.31 and a cash ratio of 11.65, indicating strong liquidity [S2].
• Net loss for Q1 2026 was $52.8 million with basic and diluted EPS of -$0.97 per share [S2].
• Celcuity has significant indebtedness, including $338.8 million aggregate principal amount as of December 31, 2025, with secured term loans and senior notes, and potential additional term loans contingent on milestones [S1].
• The company has not yet commercialized any pharmaceutical product and has no revenue; it continues to incur operating losses and relies on financing to fund operations [S1].
• Celcuity plans to market and commercialize gedatolisib in the U.S. and select international markets, either alone or with partners, targeting oncologists and related healthcare professionals [S1].
• Recent news highlights include Q1 2026 earnings call and transcript, updates on VIKTORIA-1 trial showing strong progression-free survival (PFS) benefit in PIK3CA-mutant breast cancer, and FDA acceptance of the NDA for gedatolisib with Priority Review designation [N1][N2][N3][N7].
• Citizens initiated coverage with a market outperform recommendation in April 2026 [N8].
• The company reported a wider FY25 loss but highlighted progress toward potential gedatolisib launch [N3].
• Clinical trial data presented in 2025 showed favorable safety and efficacy profiles for gedatolisib combinations in breast and prostate cancer [N7][S1].